Modus has temporarily paused enrolment in part 2 of its phase IIa study of sevuparin in CKD with anaemia after a serious adverse event in one patient, reported as a SUSAR. The proof-of-concept readout moves from around the turn of the year to Q1 2027. Modus is a small part of KDventures’ NAV, so the direct valuation effect is limited.
LÄS MER
